The Egyptian Journal of Haematology

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 42  |  Issue : 2  |  Page : 52--57

Serum visfatin in sickle cell disease: association with frequency of vaso-occlusive crises


Deena M.M. Habashy1, Marwa A Shams2 
1 Hematology Unit, Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Deena M.M. Habashy
Hematology Unit, Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, 11759
Egypt

Background Hypercoagulability in sickle cell disease (SCD) is multifactorial, involving abnormalities in platelet function, thrombin generation, fibrinolysis, and other multiple mechanisms. Visfatin, an adipocytokine with proinflammatory potential, can have a negative impact on the vascular endothelium in SCD. Objective We aimed to evaluate the association between serum visfatin level in SCD patients and the frequency of vaso-occlusive crises (VOC)/year in those patients. Patients and methods Sixteen sickle cell anemia (SCA) and 14 sickle β-plus thalassemia pediatric patients were studied in steady state. Twenty age-matched and sex-matched healthy individuals, who served as the control group, were evaluated with respect to serum visfatin levels by means of enzyme-linked immunosorbent assay. Results Hemoglobin (Hb) level was higher in the control group than in the SCA group (P<0.001), whereas total leukocyte count and serum visfatin were higher in the SCA group than in the control group (P=0.02 and <0.001, respectively). Hb level and platelet count were higher in the control group than in the sickle β thalassemia group (P<0.001 and 0.04, respectively). Serum visfatin was higher in the sickle β thalassemia group than in the control group (P<0.001). HbS%, serum visfatin, and frequency of VOC/year were higher in the SCA group than in the sickle β thalassemia group (P=0.002, <0.001, and 0.002, respectively). Serum visfatin was positively correlated with total leukocyte count, serum ferritin level, and frequency of VOC/year (P=0.005, 0.01 and 0.03, respectively) in the SCA group. Conclusion Serum visfatin is increased in SCD patients compared with that in healthy children and is associated with the frequency of VOC; it can be used as a predictive index for VOC occurrence and follow-up in those patients.


How to cite this article:
Habashy DM, Shams MA. Serum visfatin in sickle cell disease: association with frequency of vaso-occlusive crises.Egypt J Haematol 2017;42:52-57


How to cite this URL:
Habashy DM, Shams MA. Serum visfatin in sickle cell disease: association with frequency of vaso-occlusive crises. Egypt J Haematol [serial online] 2017 [cited 2020 May 26 ];42:52-57
Available from: http://www.ehj.eg.net/article.asp?issn=1110-1067;year=2017;volume=42;issue=2;spage=52;epage=57;aulast=Habashy;type=0